BBIO 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• On July 1, 2026, we entered into an Investment Agreement (the “Investment Agreement”) with Chinotto Investments, LLC (the “Sixth Street Purchaser”) and HCRx Investments HoldCo, L.P. (the “HCR Purchaser”) (collectively, the “Purchasers”), providing for the issuance and sale of Series A Cumulative Con…

• In May 2026, we filed a shelf registration statement on Form S-3 (the “2026 Shelf”) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof. We also concurrently entered into an Equity Distribution Agreement (the “…

• In May 2026, our Board of Directors approved a stock repurchase program pursuant to which we may purchase up to $500.0 million of our outstanding common stock. Stock repurchases under the program may be made from time to time, in the open market, in privately negotiated transactions and otherwise, a…

• (1)Including related party amounts of $(5,575) and $(10,936), respectively, for the three and six months ended June 30, 2026 (as described in Note 9 to our condensed consolidated financial statements).

• Total revenues, net increased by $133.1 million for the three months ended June 30, 2026, compared to the same period in 2025, which consisted of an increase of $150.9 million in net product revenue, a decrease of $31.6 million in license and services revenue, and an increase of $13.8 million in roy…

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• On May 6, 2026, our Board of Directors approved a stock repurchase program pursuant to which we may purchase up to $500.0 million of BridgeBio’s outstanding common stock. Stock repurchases under the program may be made from time to time, in the open market, in privately negotiated transactions and o…

• Noncash interest expense on deferred royalty obligations (1)$(39,873)$(24,020)

• Net loss attributable to common stockholders of BridgeBio$(164,043)$(167,422)

• (1)Including a related party amount of $(5,361) for the three months ended March 31, 2026 (as described in Note 9 to our condensed consolidated financial statements).

• Total revenues, net increased by $77.9 million for the three months ended March 31, 2026, compared to the same period in 2025, which consisted of an increase of $143.9 million in net product revenue, a decrease of $75.3 million in license and services revenue, and an increase of $9.3 million in roya…

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• The drug product for Attruby and Beyonttra is currently supplied by one primary supplier. We have entered into a master agreement with an alternative supplier of drug product and have taken delivery of commercial drug product manufactured by this secondary supplier. We expect these tablets to enter …

• Our outstanding convertible preferred stock has rights, preferences and privileges that are not held by, and are preferential to, the rights of our common stock.

• In July 2026, we issued an aggregate of 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock, par value $0.001 per share (the “Preferred Stock”), to funds managed by Sixth Street Partners, LLC, and funds managed by HealthCare Royalty, pursuant to an investment agreement (t…

• The Preferred Stock may initially be converted at any time at the option of the respective holders into an aggregate of 6,777,704 shares of our common stock. Any conversion of the Preferred Stock may significantly dilute the holders of our common stock. Unless we obtain stockholder approval in accor…

• For additional details about the Preferred Stock, refer to Note 18 to our condensed consolidated financial statements.

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• We have marked with an asterisk (*) those risk factors below that include a substantive change from or update to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 24, 2026.

• The drug product for Attruby and Beyonttra is currently supplied by one primary supplier. Although we have entered into a master agreement with an alternative supplier of drug product for this commercial product and expect the initial commercial batch of this material to be released to us later this…